Navigation Links
Spherix Announces Third Quarter Financial Results
Date:11/11/2011

rics, the Company's pharmaceutical development subsidiary.  The decrease in R&D was attributed to lower spending following completion of a Phase 3 clinical trial and a Phase 2 dose-ranging trial to develop D-tagatose for the treatment of Type 2 diabetes.  Third quarter 2011 R&D expense is related to the Company's preclinical trials for the use of both D-tagatose and SPX106 in lowering triglyceride levels.  D-Tagatose, a naturally occurring sugar, is a low-calorie, full-bulk sweetener previously approved by the Food and Drug Administration (FDA) as a GRAS (Generally Recognized as Safe) food ingredient.

The net loss for the nine months ended September 30, 2011 was $2.2 million or $0.86 per share, compared with a net loss for the nine months ended September 30, 2010 of $6.8 million or $3.99 per share.  R&D expense for the first nine months of 2011 was $1.1 million, down from $4.3 million in the comparable prior year period due to completion of the aforementioned clinical trials.

The Company had cash and cash equivalents of $5.0 million and working capital of $4.7 million as of September 30, 2011, compared with $5.6 million and $4.9 million, respectively, as of December 31, 2010.  The Company raised $2.5 million, net of offering costs, in a registered direct offering of common stock and warrants during the first quarter of 2011.  In addition, the Company subsequently raised $1.15 million, net of offering costs, in a private placement of common stock and warrants in October 2011.

Management CommentaryRobert Lodder, Ph.D., President of Spherix, noted that "The Company is pursuing opportunities to diversify and strengthen its pipeline, adding value for the shareholders."

"The excellent preclinical results we are generating from our compound, SPX-106T, which is a combination of SPX-106 and D-tagatose, is a key achievement of the third quarter and recent weeks," commented Claire Kruger, Ph.D., Chief Exe
'/>"/>

SOURCE Spherix Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Spherix Announces Closing of Private Placement of $1.25 Million, Discusses Use of Proceeds
2. Spherix to Raise $1.25 Million in Private Placement
3. Spherix Announces Results from New Preclinical Studies Showing SPX-106T Produces Significant Reductions in Cholesterol, Fat Deposition and Body Weight
4. Spherix Announces Annual Shareholders Meeting Date
5. Spherix to Present at the 5th Lippert/Heilshorn Life Sciences & Medical Technologies Virtual Conference on June 16
6. Spherix Regains Compliance With NASDAQ Listing Rule
7. Spherix Announces First Quarter Financial Results
8. Spherix Announces Reverse Stock Split Effective May 6, 2011
9. Spherix to Effect Reverse Stock Split
10. Spherix Announces 2010 Financial Results
11. Spherix to Present at the BIO-Windhover/Pharmaceutical Strategic Outlook 2011 Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Today, TiFiber, Inc. announced ... and future company headquarters in Fort Smith, Arkansas ... that safely and effectively control dangerous microorganisms. Fort ... historic, strong support for manufacturing, but also due ... technology-based companies such as TiFiber. , In ...
(Date:12/19/2014)... In contrast to traditional LED lights where ... Valoya uses proprietary LED technology to incorporate their spectra ... which is critical in low proximity installations. The Valoya ... its lifetime which is up to four times longer ... investment cost was clearly higher when compared to traditional ...
(Date:12/19/2014)... , Dec. 18, 2014   ISN ... & Safety Performance Indicators publication series. With ... of activity reported in 2013 within its online contractor ... and safety key performance indicator (KPI) statistics. ... Clients, U.S. publication is available in two ...
(Date:12/17/2014)... TX (PRWEB) December 17, 2014 Achim ... and administration for Stoller Group. In this position, Noack ... Group, on administrative matters, develop marketing strategy and supervise ... services. , “Achim has tremendous knowledge and experience ... of Stoller Group. “His experience and innovative thinking will ...
Breaking Biology Technology:Technology Company TiFiber™ to Establish Production Facility in Fort Smith, Arkansas with Support from Local Investors 2Technology Company TiFiber™ to Establish Production Facility in Fort Smith, Arkansas with Support from Local Investors 3Technology Company TiFiber™ to Establish Production Facility in Fort Smith, Arkansas with Support from Local Investors 4ISN Releases Third Edition of US Contractor Health & Safety Performance Indicators Publication Series 2ISN Releases Third Edition of US Contractor Health & Safety Performance Indicators Publication Series 3Achim Noack Joins Stoller Group as Global Vice President of Marketing and Administration 2
... - Epizyme, Inc., a company leading the discovery and ... today announced the publication of breakthrough new research in ... (USA). The discovery, centered on the epigenetic ... of basic science into targeted therapies for the safe ...
... it took his computer to boot up, Klui began to ... store enormous quantities of data, but they are slow; every ... information is transferred from the hard disk into RAM (random ... and energy consumption runs into the hundreds of millions of ...
... 15, 2010 Celladon Corp., a biopharmaceutical company ... treatments for cardiovascular diseases, today announced that 12-month ... of MYDICAR® demonstrated significant improvements in clinical outcomes ... patients treated with the genetically-targeted enzyme replacement therapy. ...
Cached Biology Technology:Epizyme identifies novel opportunity for treatment of genetically defined human B-cell lymphomas 2Racetrack memory 2Celladon Corporation Announces MYDICAR® Enzyme Replacement Therapy for Advanced Heart Failure Provides Sustained Clinical Improvements in Patients for 12 Months Compared with Placebo 2Celladon Corporation Announces MYDICAR® Enzyme Replacement Therapy for Advanced Heart Failure Provides Sustained Clinical Improvements in Patients for 12 Months Compared with Placebo 3Celladon Corporation Announces MYDICAR® Enzyme Replacement Therapy for Advanced Heart Failure Provides Sustained Clinical Improvements in Patients for 12 Months Compared with Placebo 4
(Date:12/17/2014)... 16, 2014 Research and Markets ... the "Global Chemical Sensor Market 2015-2019" ... http://photos.prnewswire.com/prnh/20130307/600769 One major trend ... for medical sensors in biomedical applications. Chemical sensors ... and correct diagnosis during surgical procedures. The Global ...
(Date:12/11/2014)... WINSTON SALEM, N.C. , Dec. 10, 2014  That ... known for quite a while. Hypertension – the medical term ... disease in the early 1800s, and the inflatable cuff that,s ... That doesn,t, however, mean there,s nothing new about hypertension, ... punctured some long-held beliefs about the condition and the best ...
(Date:12/10/2014)... SAN DIEGO , Dec. 9, 2014 ... and collaboration catalyst that provides the connective tissue that ... by enabling them to easily share client-level information; earned ... Foundation to expand to organizations serving seniors aging in ... San Diego" partner on December 11 th 4-6p. ...
Breaking Biology News(10 mins):Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4
... created by researchers at the San Diego Supercomputer Center ... scientists to study evolutionary relationships among large populations of ... having to understand how to operate large, complex computer ... CIPRES (Cyberinfrastructure for Phylogenetic RESearch) Gateway, is ...
... The Cystic Fibrosis Foundation has awarded a Marshall University ... Dr. Hongwei Yu, professor in the Department of Biochemistry ... of Medicine, will help further his lab,s work to ... in the lungs of cystic fibrosis (CF) patients. ...
... policies governing the storage and use of surplus blood samples ... process range from explicit to non-existent, leaving many parents ill-informed ... according to a team led by a member of the ... from the University of Utah. A report on their analysis ...
Cached Biology News:SDSC's CIPRES Gateway provides window to the past -- and fast 2SDSC's CIPRES Gateway provides window to the past -- and fast 3Cystic Fibrosis Foundation funds Marshall research 2Most states unclear about storage, use of babies' blood samples, new study finds 2Most states unclear about storage, use of babies' blood samples, new study finds 3Most states unclear about storage, use of babies' blood samples, new study finds 4
... Many modifications of Eagle's medium ... original formulation. The most widely ... Eagle's,Medium. DME is a modification ... [MEM] that contains a higher ...
... The EpiTect Bisulfite Kit enables ... uracils in less than 6 hours. ... innovative protection against DNA degradation and ... to guarantee fast and reliable results ...
Rabbit polyclonal antibody to Glutathione-S-Transferase (GST)...
... gold standard for automated bioresearch: Developed ... applications • Based on decades of ... accessories designed for bioresearch • Holographic ... Versatility, reliability and ease-of-use • Pulsed ...
Biology Products: